When was CHA Biotech founded?

CHA Biotech was founded in 2000 and raised its 1st funding round 26 years after it was founded.

Where is CHA Biotech located?

CHA Biotech is headquartered in Seongnam-si, South Korea.

Is CHA Biotech a funded company?

CHA Biotech is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Jan 19, 2026.

When was the latest funding round of CHA Biotech?

CHA Biotech's latest funding was a $***** Post IPO round on Jan 19, 2026, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In South Korea, the Life Sciences Platforms and Tools sector has seen $110M in funding in 2026 to date.

Where does CHA Biotech rank among its competitors?

CHA Biotech ranks 59th amongst 1957 active competitors, of which 452 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of CHA Biotech?

CHA Biotech's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

CHA Biotech - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of stem cell therapeutics. The company's pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The company's adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetal–NPC (Nerve Progenitor Cell) for Parkinson's disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.

Website: chabio.com
Phone Number: +82 **********

Key Metrics

Founded Year

2000

Location

Seongnam-si, South Korea

Stage

Public

Latest Funding Round

Post IPO, Jan 19, 2026, $*****

Investors

Hanwha Life & 4 more

Ranked

59^th among 1957 active competitors

Similar Companies

Synthego & 2666 more

Exit Details

Public

View CHA Biotech's full profile

CHA Biotech got listed on Dec 27, 2005.

Click here to take a look at CHA Biotech's IPO in detail

CHA Biotech has raised funding over 1 round. Its latest funding round was a Post IPO round on Jan 19, 2026 for $*****. 1 investor participated in its latest round. CHA Biotech has 5 institutional investors.

Here is the list of recent funding rounds of CHA Biotech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 19, 2026	2256879	Post IPO	6658301	8122711	8308969	3412251

Access funding benchmarks and valuations. Sign up today!

View details of CHA Biotech's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CHA Biotech include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of CHA Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
59th	CHA Biotech 2000, Seongnam-si (South Korea), Public	Developer of stem cell therapeutics	-	Hanwha Life, GNTech Venture Capital & 3 others	54/100